The Medical Letter on Drugs and Therapeutics
Ferric Carboxymaltose (Injectafer) for Iron Deficiency Anemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ferric carboxymaltose (Injectafer – American Regent), a 2-dose intravenous iron replacement product, for treatment of iron deficiency anemia (IDA) in adults who cannot tolerate or have had an unsatisfactory response to oral iron and in those who have non-dialysis-dependent chronic kidney disease (CKD). It is the sixth IV iron product approved in the US.

IV IRON SUPPLEMENTATION — IV iron is prescribed for patients with IDA who cannot absorb or tolerate oral iron or who have unresolved bleeding.1 For patients with non-dialysis-dependent CKD, the route of iron administration is based on the severity of iron deficiency, availability of venous access, response to prior therapies, patient adherence, and cost.2 Most IV iron preparations are given in 3-10 infusions over multiple weeks. Ferumoxytol (Feraheme) ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ferric Carboxymaltose (Injectafer) for Iron Deficiency Anemia
Article code: 1431d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian